Cara Therapeutics Employee Directory
Biotechnology ResearchConnecticut, United States51-200 Employees
Cara Therapeutics is a mid-sized biotechnology company based in Stamford, Connecticut, focused on developing treatments for pruritus. Its portfolio includes an oral formulation of difelikefalin for chronic pruritus associated with notalgia paresthetica, pursued in a Phase 2/3 program with topline dose-finding results expected in the third quarter of 2024. Additionally, the firm has developed an intravenous difelikefalin formulation that is approved for moderate-to-severe pruritus in adults undergoing hemodialysis due to advanced chronic kidney disease, with the IV product licensed worldwide. As a development-stage player in the biotechnology research space, Cara operates with a focus on pruritus-related conditions and related therapies. In March 2025, Cara announced a merger with Tvardi Therapeutics, with completion expected in the first half of the year.
1-888-653-2347 
support@leadiq.com 
